My Portfolio

Abivax SA ABVX-FR:Euronext Paris

*Data is delayed | Exchange | EUR

Last | 9:16 AM CEST

79.65

+8.40 (+11.79%)

Volume

168,807

52 week range

5.12 - 132.00

Open77.50
Day High81.55
Day Low76.55
Prev Close71.25
52 Week High132.00
52 Week High Date01/12/26
52 Week Low5.12
52 Week Low Date06/23/25

Latest On Abivax SA

Biotech Abivax sinks 43% as cancer cases cloud trial data for bowel disease drugJune 2, 2026CNBC.com
European stocks close higher as oil prices slip; Abivax shares collapse June 2, 2026CNBC.com
Dow jumps more than 200 points, S&P 500 posts first close above 7,600June 1, 2026CNBC.com
AI frenzy sees these European stocks soar this year in blockbuster rallyMay 21, 2026CNBC.com
Abivax in no rush for a deal, confident June trial data can secure better terms, CEO saysMarch 24, 2026CNBC.com
Monday's biggest analyst calls: Nvidia, Micron, Meta, Qualcomm, Palantir, Amazon, Upstart March 16, 2026CNBC.com
This biotech stock is up 1,000% since late July. Jefferies sees more gains aheadMarch 16, 2026CNBC.com
Abivax denies French media report of AstraZeneca takeoverMarch 12, 2026CNBC.com
European stocks finish lower as oil prices jump March 12, 2026CNBC.com
The top 10 analysts of 2025, as measured by TipRanksJanuary 25, 2026CNBC.com

Key Stats

Market Cap6.354B
Shares Out79.77M
10 Day Average Volume0.62M
Dividend-
Dividend Yield-
Beta1.94

Latest On Abivax SA

Biotech Abivax sinks 43% as cancer cases cloud trial data for bowel disease drugJune 2, 2026CNBC.com
European stocks close higher as oil prices slip; Abivax shares collapse June 2, 2026CNBC.com
Dow jumps more than 200 points, S&P 500 posts first close above 7,600June 1, 2026CNBC.com
AI frenzy sees these European stocks soar this year in blockbuster rallyMay 21, 2026CNBC.com
Abivax in no rush for a deal, confident June trial data can secure better terms, CEO saysMarch 24, 2026CNBC.com
Monday's biggest analyst calls: Nvidia, Micron, Meta, Qualcomm, Palantir, Amazon, Upstart March 16, 2026CNBC.com
This biotech stock is up 1,000% since late July. Jefferies sees more gains aheadMarch 16, 2026CNBC.com
Abivax denies French media report of AstraZeneca takeoverMarch 12, 2026CNBC.com
European stocks finish lower as oil prices jump March 12, 2026CNBC.com
The top 10 analysts of 2025, as measured by TipRanksJanuary 25, 2026CNBC.com

KEY STATS

Open77.50
Day High81.55
Day Low76.55
Prev Close71.25
52 Week High132.00
52 Week High Date01/12/26
52 Week Low5.12
52 Week Low Date06/23/25
Market Cap6.354B
Shares Out79.77M
10 Day Average Volume0.62M
Dividend-
Dividend Yield-
Beta1.94

RATIOS/PROFITABILITY

EPS (TTM)-4.62
P/E (TTM)-17.23
Fwd P/E (NTM)-
EBITDA (TTM)-253.886M
ROE (TTM)-157.07%
Revenue (TTM)-
Gross Margin (TTM)-
Net Margin (TTM)-
Debt To Equity (MRQ)0.34%

EVENTS

Earnings Date-
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Abivax price target lowered to $136 from $176 at Wolfe Research14 Hours AgoTipRanks
Abivax rises 13.1%15 Hours AgoTipRanks
Abivax rises 14.1%16 Hours AgoTipRanks
Abivax falls -45.0%June 2, 2026TipRanks
Abivax falls -40.3%June 2, 2026TipRanks

Profile

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine...

Sylvie Gregoire Pharm.D.

Chairwoman of the Board

Marc De Garidel

Chief Executive Officer

Didier Blondel

Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors

Jerome Denis Ph.D.

Executive Vice President - Process Development & Manufacturing

Address

7-11 Boulevard Haussmann

Paris

75009

France

https://www.abivax.com/